Novartis says positive interim results on rare kidney disease drug

IgAN is a rare autoimmune disease mostly affecting young adults, which can lead to kidney failure. The study is to continue for a further 15 months. In total, it will cover around 450 adult patients with primary IgAN who are at high risk of progressing to kidney failure.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/wh5oVPX
via